8of 10
The top decile of pharma labs in Chile commercializes 8 of every 10 registrations they maintain. The average lab? Just 4.
From registration to revenue.
THE GAP
The bottleneck isn't regulatory.
Chile's ISP approves 95% of pharmaceutical registration applications. Markets are open.
Yet the median lab commercializes only 4 of every 10 registrations it maintains. The difference between the top decile and the average isn't access — it's portfolio strategy. Which molecules to register, which to commercialize first, which to ramp up, which to suspend, who to partner with.
Source: 32,362 ISP registrations, 142,163 public tenders, 42,283 pharmaceutical imports — Lanin Pharma dataset
WHAT LANIN PHARMA DOES
Three layers of precision.
Granular market intelligence
Every public tender, every pharmaceutical import, every ISP registration in Chile from the last 5 years. Cleaned, normalized, queryable.
Forecasting & continuous intelligence
Hit rate per registration. Win probability per molecule per buyer type. Stockout risk scores. 12–36 month commercial forecasts per molecule, refreshed continuously. Real-time competitive alerts on your portfolio.
Pre-validated distributor network
Chilean commercial partners ranked by therapeutic area fit, recent activity, and historical reliability. The connection layer most labs spend months building manually.
FOR PORTFOLIO TEAMS
Built for pharma labs that maximize every registration's commercial potential.
If you commercialize molecules in Chile — already active, scaling, or evaluating entry — Lanin Pharma exists for you.
Lanin Pharma is built for portfolio strategy, BD, and commercial teams making continuous decisions in Chile: which molecules to commercialize next, which to suspend, when to move on a competitor's exit. Chile-focused today, expanding across LATAM.
- Forecast each molecule's commercial value over 12, 24, 36 months — and refresh when the market shifts
- Real-time alerts when competitors enter, exit, or move on molecules in your portfolio
- Read public tender dynamics — bid timing, winner patterns, pricing benchmarks — across CENABAST and public hospital procurement
- Identify which registrations already on your shelf deserve more commercial push — and which to suspend
- Spot the 10–15 molecules worth registering next, with confidence intervals
“The data is the easy part. The strategy is not.”
- Atorvastatin+58pts
- Metformin+47pts
- Losartan+41pts
- Omeprazole+38pts
of active molecules in Chile have ≤2 suppliers — 1,668 entry-ready therapeutic gaps.
- Comercializadora Aoncology
- Comercializadora Bcardio · diabetes
- Comercializadora Crespiratory
HOW IT WORKS
Four steps from data to deal.
- 01
Discovery
You access the platform with a tier matched to your portfolio scope.
- 02
Portfolio analysis
Lanin Pharma evaluates your current Chilean registrations (or your shortlist) against market data.
- 03
Recommendations
Receive ranked opportunities: which molecules to commercialize first, what tender approach to take, which distributors to approach.
- 04
Continuous engagement
Quarterly portfolio reviews, real-time competitive alerts, and on-demand introductions to Chilean distributors when relevant.
LAUNCH TIMELINE
Currently in beta. General access opens Q3 2026.
We're working with a select group of design partners through August 2026 to refine the platform. Public launch is scheduled for September 2026.
- May 2026Beta with design partnersCurrent
- Jul 2026First quarterly report published
- Sep 2026General launch
Join the waitlist to receive launch updates and early access.
NEW — LANIN INSIGHTS
We're publishing our research notes on Chile's public-pharma market.
Independent analysis built from the public record. The first issue measures how competitive CENABAST procurement really is — how much is actually tendered, and what thin competition costs.
If this is your world and you want to go deeper, reach out through the page — we're happy to talk.
EARLY ACCESS
Be among the first to use Lanin Pharma.
Join the waitlist to receive quarterly market reports, launch updates, and early access invitations.
We respect your inbox. No spam, no third-party sharing. Unsubscribe anytime.